Darovasertib, a novel treatment for metastatic uveal melanoma

The FDA granted orphan drug designation to darovasertib, a first-in-class oral, small molecular inhibitor of protein kinase C (PKC), for the treatment of uveal melanoma, on 2 May 2022. Primary uveal melanoma has a high risk of progressing to metastatic uveal melanoma, with a poor prognosis. The acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Lei, Chen, Shuzhen, Sun, Rainie, Ashby, Charles R., Wei, Liuya, Huang, Zoufang, Chen, Zhe-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419210/
https://www.ncbi.nlm.nih.gov/pubmed/37576814
http://dx.doi.org/10.3389/fphar.2023.1232787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419210/
https://www.ncbi.nlm.nih.gov/pubmed/37576814
http://dx.doi.org/10.3389/fphar.2023.1232787

Ejemplares similares